Status:
UNKNOWN
Colonic Glucose vs. Saline Infusion
Lead Sponsor:
Qilu Hospital of Shandong University
Conditions:
Gastrointestinal Hormones
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The distal ileum and proximal colon, where the glucagon-like peptide 1 (GLP-1) releasing cells predominate, are important organs in mediating glycemic control. The proximal colon is not easy to access...
Eligibility Criteria
Inclusion
- Male and postmenopausal females aged 18 - 75 years
- Body mass index (BMI) 20 - 35 kg/m2
- With protective ileostomy due to benign or malignant rectal surgery
Exclusion
- History of postoperative adjuvant chemotherapy
- Other significant illness, including epilepsy, cardiovascular or respiratory disease
- Impaired renal or liver function (as assessed by calculated creatinine clearance \< 90 mL/min or abnormal liver function tests (\> 2 times upper limit of normal range))
- Donation of blood within the previous 3 months
- Participation in any other research studies within the previous 3 months
- Females who are pre-menopausal
- Inability to give informed consent
- Vegetarians
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05302206
Start Date
April 1 2022
End Date
August 1 2022
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012